These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15917657)

  • 1. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
    Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
    Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
    Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
    Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.
    Dhanikula AB; Singh DR; Panchagnula R
    Curr Drug Deliv; 2005 Jan; 2(1):35-44. PubMed ID: 16305406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
    J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.
    Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
    Int J Pharm; 2019 Jun; 565():219-226. PubMed ID: 31077761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
    Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of paclitaxel in plasma and cerebrospinal fluid.
    Gelderblom H; Baker SD; Zhao M; Verweij J; Sparreboom A
    Anticancer Drugs; 2003 Jun; 14(5):365-8. PubMed ID: 12782943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
    Gelderblom H; Verweij J; Nooter K; Sparreboom A
    Eur J Cancer; 2001 Sep; 37(13):1590-8. PubMed ID: 11527683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.